Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2) : week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials